Back to search

Article

Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants

2022-09-06

Abstract excerpt

<h4>ABSTRACT</h4> <h4>BACKGROUND</h4> The rising breakthrough infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, especially Omicron and its sub-lineages, have raised an urgent need to develop broad-spectrum vaccines against coronavirus disease 2019 (COVID-19) . We have developed a mosaic-type recombinant vaccine candidate, named NVSI-06-09, having immune potentials against...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
00d8a725-5288-503d-aa0a-f2c8464e351c
DOI
10.1101/2022.09.05.22279589
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variantsDOI 10.1101/2022.09.05.22279589
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trialSemantic proximity
<strong>Efficacy of COVID-19 Vaccines Against the Omicron Variant of SARS-CoV-2</strong>Semantic proximity
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: a randomized controlled phase 2 trialSemantic proximity
Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b TrialSemantic proximity
Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineagesSemantic proximity
Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic reviewSemantic proximity
The Efficacy for the Booster Dose of Covid-19 Vaccine between Sars-Cov-2 Omicron Variant and a Two-Year Longitudinal Antibody on Wild Type ConvalescentsSemantic proximity
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesSemantic proximity
Expert Review of Global Real-World Data on COVID-19 Vaccine Booster Effectiveness &amp; Safety During the Omicron-dominant Phase of the PandemicSemantic proximity
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boostSemantic proximity
Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron VariantSemantic proximity
Select a neighboring publication to make it the new centre.